Cargando…

IL-27 induces LL-37/CRAMP expression from intestinal epithelial cells: implications for immunotherapy of Clostridioides difficile infection

Clostridioides difficile infection is currently the leading cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis worldwide. Cathelicidins, a major group of natural antimicrobial peptides, have antimicrobial and immunomodulatory activities in Clostridioides difficile infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Banglao, Wu, Xianan, Gong, Yi, Cao, Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405154/ https://www.ncbi.nlm.nih.gov/pubmed/34432564 http://dx.doi.org/10.1080/19490976.2021.1968258

Ejemplares similares

Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection
por: Castro-Córdova, Pablo, et al.
Publicado: (2021)

The C. difficile clnRAB operon initiates adaptations to the host environment in response to LL-37
por: Woods, Emily C., et al.
Publicado: (2018)

Design and characterization of a new hybrid peptide from LL-37 and BMAP-27
por: Al Tall, Yara, et al.
Publicado: (2019)

Gut epithelial IL-27 confers intestinal immunity through the induction of intraepithelial lymphocytes
por: Lin, Chia-Hao, et al.
Publicado: (2021)

Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy
por: Findlay, Emily Gwyer, et al.
Publicado: (2019)

The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure
por: Zhou, Qiulian, et al.
Publicado: (2020)

Enhancement of the activity of the antimicrobial peptides HNP1 and LL-37 by bovine pancreatic ribonuclease A
por: Ericksen, Bryan
Publicado: (2023)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
por: Sahrmann, John M, et al.
Publicado: (2023)

Intestinal Microbiota in Elderly Inpatients with Clostridioides difficile Infection
por: Vakili, Bahareh, et al.
Publicado: (2020)

Author Correction: Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection
por: Castro-Córdova, Pablo, et al.
Publicado: (2022)

Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
por: Lande, Roberto, et al.
Publicado: (2020)

Clostridioides difficile Prevalence in the United States: National Inpatient Sample, 2016 to 2018
por: Petersen, Molly R, et al.
Publicado: (2021)

Association between Antibiotic Consumption and Incidence of Clostridioides difficile Infection in a Hospital
por: Kim, Bongyoung, et al.
Publicado: (2020)

Effect of Reduced Fluoroquinolone Use on Cephalosporin Use, Susceptibilities and Clostridioides difficile Infections
por: Wren, Callyn Mariah, et al.
Publicado: (2022)

Genomic evolution and virulence association of Clostridioides difficile sequence type 37 (ribotype 017) in China
por: Xu, Xingxing, et al.
Publicado: (2021)

The Role of Cathelicidin LL-37 in Cancer Development
por: Piktel, Ewelina, et al.
Publicado: (2015)

Significance of LL-37 on Immunomodulation and Disease Outcome
por: Yang, Binbin, et al.
Publicado: (2020)

Regulation of LL-37 in Bone and Periodontium Regeneration
por: Chinipardaz, Zahra, et al.
Publicado: (2022)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections
por: Wendt, Sebastian, et al.
Publicado: (2020)

Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019
por: Allegretti, Jessica R, et al.
Publicado: (2021)

Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice
por: Drewes, Julia L., et al.
Publicado: (2022)

A Post–Liver Transplant Girl With Recurrent Cramps in the Legs
por: Abe, Jiro, et al.
Publicado: (2015)

Cramps
Publicado: (1859)

Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
por: Huus, Kelsey E, et al.
Publicado: (2020)

Deep hyperammonemic hepatic encephalopathy precipitated by fecal microbiota transplantation for fulminant Clostridioides difficile infection
por: Eriksen, Lotte Lindgreen, et al.
Publicado: (2021)

Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes
por: Bernard, Rachel, et al.
Publicado: (2022)

Impact of suppressing ciprofloxacin susceptibility results on antibiotic utilization and hospital-acquired Clostridioides difficile infection
por: White, Bryan P., et al.
Publicado: (2021)

Treatment of Extra-Intestinal Clostridioides difficile Abscess following Acute Appendicitis
por: Chatterjee, Tulika, et al.
Publicado: (2022)

Prevalence of Clostridioides difficile in Canine Feces and Its Association with Intestinal Dysbiosis
por: Werner, Melanie, et al.
Publicado: (2023)

Cathelicidin LL-37 in Health and Diseases of the Oral Cavity
por: Tokajuk, Joanna, et al.
Publicado: (2022)

Serum LL‐37 and inflammatory cytokines levels in psoriasis
por: Lao, Juanfeng, et al.
Publicado: (2023)

LL-37 Triggers Antimicrobial Activity in Human Platelets
por: Sánchez-Peña, Francisco Javier, et al.
Publicado: (2023)

CXCR2 specific endocytosis of immunomodulatory peptide LL-37 in human monocytes and formation of LL-37 positive large vesicles in differentiated monoosteophils
por: Zhang, Zhifang, et al.
Publicado: (2019)

Iron Regulation in Clostridioides difficile
por: Berges, Mareike, et al.
Publicado: (2018)

Extraintestinal Clostridioides difficile infection
por: Hai, Zhao, et al.
Publicado: (2020)

Pathogenicity and virulence of Clostridioides difficile
por: Buddle, Jessica E., et al.
Publicado: (2023)

Detection of Free Toxin B in the Stool of Asymptomatic Clostridioides difficile Carriers by the Cell Cytotoxicity Neutralization Assay
por: Schweitzer, Lorne, et al.
Publicado: (2021)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1slvdembq8n2hjoddbu6qe1jg